EnteroBiotix is a clinical stage microbiome therapeutics company. It leverages the gut microbiome to develop novel medicinal products that restore health and prevent disease, with a specific focus on drug-resistant bacterial infections and gastrointestinal conditions. The company uses its MHRA-licensed platform capabilities and patent-pending technology to advance three core product portfolios that build on the science of the medical treatment known as fecal microbiota transplantation.
|Employees (est.) (Jan 2021)||16|
EnteroBiotix total Funding
EnteroBiotix latest funding size
Time since last funding
|2 years ago|
|Scottish Investment Bank, Equity Gap, Barwell Plc, Fund Twenty8, the University of Aberdeen, Bank Workers Charity, Gabriel, Syndicate Room, NCIMB Limited, SIS Ventures|
EnteroBiotix has 976 Twitter Followers. The number of followers has decreased 0.2% month over month and increased 0.1% quarter over quarter
When was EnteroBiotix founded?
EnteroBiotix was founded in 2017.
Who are EnteroBiotix key executives?
EnteroBiotix's key executives are Michael J. Butler, Gregor Russell and James R. McIlroy.
How many employees does EnteroBiotix have?
EnteroBiotix has 16 employees.
Who are EnteroBiotix competitors?
Competitors of EnteroBiotix include Cybele Microbiome, ZeCardio Therapeutics and AiCuris.
Where is EnteroBiotix headquarters?
EnteroBiotix headquarters is located at Foresterhill Rd, Foresterhill.
Where are EnteroBiotix offices?
EnteroBiotix has an office in Foresterhill.
How many offices does EnteroBiotix have?
EnteroBiotix has 1 office.
Receive alerts for 300+ data fields across thousands of companies